NPS Pharmaceuticals, Inc.  

(Public, NASDAQ:NPSP)   Watch this stock  
Find more results for GEORGE A. NADER�
32.31
+0.31 (0.97%)
Real-time:   11:33AM EST
NASDAQ real-time data - Disclaimer
Currency in USD
Range 31.95 - 32.67
52 week 22.11 - 39.68
Open 32.02
Vol / Avg. 411,835.00/1.85M
Mkt cap 3.41B
P/E 3,214.98
Div/yield     -
EPS 0.01
Shares 106.84M
Beta 0.73
Inst. own 101%
Feb 16, 2015
Q4 2014 NPS Pharmaceuticals Inc Earnings Release (Estimated) - 12:00AM EST - Add to calendar
Nov 20, 2014
NPS Pharmaceuticals Inc at Jefferies Global Healthcare Conference - London
Nov 10, 2014
Q3 2014 NPS Pharmaceuticals Inc Earnings Call
Nov 10, 2014
Q3 2014 NPS Pharmaceuticals Inc Earnings Release
Oct 1, 2014
NPS Pharmaceuticals Inc at Leerink Rare Disease Roundtable
Sep 12, 2014
NPS Pharmaceuticals Inc Conference Call to discuss FDA Advisory Committee to Review Natpara� Biologics License Application
Sep 12, 2014
NPS Pharmaceuticals Inc FDA Advisory Committee Meeting
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -3.75% -8.68%
Operating margin 2.36% -0.96%
EBITD margin - 0.73%
Return on average assets -3.02% -6.09%
Return on average equity -6.62% -53.75%
Employees 207 -
CDP Score - -

Address

550 HILLS DRIVE
BEDMINSTER, NJ 07921
United States - Map
+1-908-4505300 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

NPS Pharmaceuticals, Inc. (NPS) is a biopharmaceutical company focused on pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide. The Company�s primary product Gattex 0.05 mg/kg/d (teduglutide [rDNA origin]) for injection, for subcutaneous use was approved by the United States Food and Drug Administration (FDA) during the year ended December 31, 2012, for the treatment of adult patients with short bowel syndrome (SBS) who are dependent on parenteral support. Natpara is the recombinant full-length human parathyroid hormone (rhPTH (1-84)), which is developing as a hormone replacement therapy for hypoparathyroidism, a rare hormone deficiency disorder, in which patients are physiologically unable to regulate the levels of calcium and phosphates in their blood due to insufficient levels of endogenous parathyroid hormone (PTH).

Officers and directors

Peter G. Tombros Independent Chairman of the Board
Age: 71
Bio & Compensation  - Reuters
Francois Nader M.D. President, Chief Executive Officer, Director
Age: 57
Bio & Compensation  - Reuters
Luke M. Beshar CPA Chief Financial Officer, Executive Vice President
Age: 55
Bio & Compensation  - Reuters
Roger J. Garceau M.D. Executive Vice President, Chief Medical Officer
Age: 60
Bio & Compensation  - Reuters
Christine Mikail Senior Vice President - Legal Affairs, General Counsel
Bio & Compensation  - Reuters
Glenn R. Melrose Senior Vice President - Human Resources
Age: 58
Bio & Compensation  - Reuters
Eric Pauwels Chief Commercial Officer, Senior Vice President
Age: 52
Bio & Compensation  - Reuters
Joseph J. Rogus Vice President - Technical Operations and Supply Chain Management
Age: 67
Bio & Compensation  - Reuters
Susan E. Graf Vice President - Corporate Development and Strategy
Age: 41
Bio & Compensation  - Reuters
Pierre Legault CPA Director
Age: 54
Bio & Compensation  - Reuters